Anebulo Pharmaceuticals I... (ANEB)
1.60
0.05 (3.23%)
At close: Jan 14, 2025, 2:21 PM
1.60
0.00%
After-hours Jan 14, 2025, 02:21 PM EST
undefined% (undefined)
| Bid | 1.26 |
| Market Cap | 41.38M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | -5.32 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.75 |
| Volume | 1,301 |
| Avg. Volume (20D) | 27,398 |
| Open | 1.53 |
| Previous Close | 1.55 |
| Day's Range | 1.53 - 1.60 |
| 52-Week Range | 0.80 - 3.30 |
| Beta | undefined |
About ANEB
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas....
Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2021
Employees 2
Stock Exchange NASDAQ
Ticker Symbol ANEB
Website https://www.anebulo.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ANEB stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 50.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-1.94%
Anebulo Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
